Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3994 Outlook for 615 small intestinal neuroendocrine tumor patients: Recurrence risk after surgery and disease-specific survival in advanced disease

Introduction: Small intestinal neuroendocrine tumors (siNET) are one of the most common neuroendocrine neoplasms. Radical surgery is the only curative treatment.

Conference:

Presenting Author: Andreassen M

Authors: Slott C, Langer S, Møller S, Krogh J, Klose M,

Keywords: Small intestinal neuroendocrine tumor survival, prognosis, recurrence,

#3992 Recurrence free survival and disease-specific survival in patients with pancreatic neuroendocrine neoplasms: A single center retrospective study of 413 patients

Introduction: The prognosis and impact of different prognostic factors in pancreatic neuroendocrine neoplasms (pNEN) remains controversial.

Conference:

Presenting Author: Andreassen M

Authors: Møller S, Langer S, Slott C, Krogh J, Palnæs Hansen C,

Keywords: Pancreatic neuroendocrine neoplasms incidence, clinical presentation, prognosis,

#3838 Subgroup analysis of ORR and PFS of the SEQTOR study (GETNE 1206) – Everolimus followed by Streptozotocin (STZ)-5FU upon progression or the reverse sequence, in advanced progressive panNETs

Introduction: Previous global results of ORR and PFS1 have been presented. The best treatment (Tx) sequence between STZ-5FU and everolimus (EVE) in patients (pts) with advanced and progressive panNETs is not yet well established.

Conference:

Presenting Author: Salazar R

Authors: Capdevila J, Tafuto S, Krogh M, Teulé A, Garcia-Carbonero R,

Keywords: panNET, everolimus, STZ-5FU,

#3634 Imaging surveillance in multiple endocrine neoplasia type 1 – 10 years of experience with somatostatin receptor positron emission tomography

Introduction: Guidelines for multiple endocrine neoplasia type 1 (MEN1) recommend intensive imaging surveillance without specifying a superior regimen, including the role of somatostatin receptor imaging (SRI) with positron emission tomography (PET).

Conference:

Presenting Author: Andreassen M

Authors: Said M, Krogh J, Feldt-Rasmussen U, Rasmussen �, Kristensen T,

Keywords: Imaging, Multiple endocrine neoplasia type 1, Neuroendocrine neoplasm, Positron emission tomography, Somatostatin receptor,

#3507 Phase II study of everolimus and temozolomide as 1-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms (NET G3 and NEC)

Introduction: High-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN) consist of poorly differentiated neuroendocrine carcinoma (NEC) and well-differentiated neuroendocrine tumors (NET G3). Platinum/etoposide has been the cornerstone of treatment in advanced cases, but show limited benefit for patients when tumors have Ki-67 ≤55%.

Conference:

Presenting Author:

Authors: Morken S, Langer S, Sundlöv A, Detlefsen S, Krogh M,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, high-grade gastroenteropancreatic, everolimus, temozolomide,